カテゴリ： 世界, 医療/バイオ, Market Monitor Global

処方片頭痛薬のグローバル市場展望 2023年-2029年：スマトリプタン、リザトリプタン、その他

■ 英語タイトル：Prescription Migraine Medication Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC14530）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC14530
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品
■ ページ数：68
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[処方片頭痛薬のグローバル市場展望 2023年-2029年：スマトリプタン、リザトリプタン、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の処方片頭痛薬市場規模と予測を収録しています。・世界の処方片頭痛薬市場：売上、2018年-2023年、2024年-2029年
・世界の処方片頭痛薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の処方片頭痛薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「スマトリプタン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

処方片頭痛薬のグローバル主要企業は、GSK、 Teva、 Pfizer、 Amgen、 Viatris、 Allergan、 Grunenthal、 Eli Lillyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、処方片頭痛薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の処方片頭痛薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の処方片頭痛薬市場：タイプ別市場シェア、2022年
・スマトリプタン、リザトリプタン、その他

世界の処方片頭痛薬市場：用途別、2018年-2023年、2024年-2029年
世界の処方片頭痛薬市場：用途別市場シェア、2022年
・病院、診療所、ドラッグストア

世界の処方片頭痛薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の処方片頭痛薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における処方片頭痛薬のグローバル売上、2018年-2023年
・主要企業における処方片頭痛薬のグローバル売上シェア、2022年
・主要企業における処方片頭痛薬のグローバル販売量、2018年-2023年
・主要企業における処方片頭痛薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GSK、 Teva、 Pfizer、 Amgen、 Viatris、 Allergan、 Grunenthal、 Eli Lilly

*************************************************************

・調査・分析レポートの概要
処方片頭痛薬市場の定義
市場セグメント
世界の処方片頭痛薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の処方片頭痛薬市場規模
世界の処方片頭痛薬市場規模：2022年 VS 2029年
世界の処方片頭痛薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの処方片頭痛薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の処方片頭痛薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：スマトリプタン、リザトリプタン、その他
処方片頭痛薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、ドラッグストア
処方片頭痛薬の用途別グローバル売上・予測

・地域別市場分析
地域別処方片頭痛薬市場規模 2022年と2029年
地域別処方片頭痛薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、 Teva、 Pfizer、 Amgen、 Viatris、 Allergan、 Grunenthal、 Eli Lilly
...

This research report provides a comprehensive analysis of the Prescription Migraine Medication market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Prescription Migraine Medication market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Prescription Migraine Medication, challenges faced by the industry, and potential opportunities for market players.
The global Prescription Migraine Medication market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Prescription Migraine Medication market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Prescription Migraine Medication market. Additionally, the growing consumer demand present avenues for market expansion.
The global Prescription Migraine Medication market was valued at US$ 1155.4 million in 2022 and is projected to reach US$ 1574.6 million by 2029, at a CAGR of 4.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Headaches and migraines are common conditions affecting a significant portion of the population. The increasing prevalence of these conditions drives the demand for prescription headache medicines as individuals seek effective treatment options to manage their symptoms. While over-the-counter medications can provide relief for many individuals with mild headaches, there is a substantial population that experiences moderate to severe headaches or migraines that require stronger prescription medications. The unmet medical needs of this population drive the demand for prescription headache medicines.
Key Features:
The research report on the Prescription Migraine Medication market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Prescription Migraine Medication market.
Market Overview: The report provides a comprehensive overview of the Prescription Migraine Medication market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Sumatriptan, Rizatriptan), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Prescription Migraine Medication market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Prescription Migraine Medication market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Prescription Migraine Medication market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Prescription Migraine Medication market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Prescription Migraine Medication market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Prescription Migraine Medication market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Prescription Migraine Medication, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Prescription Migraine Medication market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Prescription Migraine Medication market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Sumatriptan
Rizatriptan
Others
Market segment by Application
Hospital
Clinic
Drug Store
Global Prescription Migraine Medication Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East＆Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East＆Africa
Major players covered
GSK
Teva
Pfizer
Amgen
Viatris
Allergan
Grunenthal
Eli Lilly
Outline of Major Chapters:
Chapter 1: Introduces the definition of Prescription Migraine Medication, market overview.
Chapter 2: Global Prescription Migraine Medication market size in revenue.
Chapter 3: Detailed analysis of Prescription Migraine Medication company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Prescription Migraine Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research＆Analysis Reports
1.1 Prescription Migraine Medication Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Prescription Migraine Medication Market Overview
1.4 Features＆Benefits of This Report
1.5 Methodology＆Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions＆Caveats
2 Global Prescription Migraine Medication Overall Market Size
2.1 Global Prescription Migraine Medication Market Size: 2022 VS 2029
2.2 Global Prescription Migraine Medication Market Size, Prospects＆Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities＆Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Prescription Migraine Medication Players in Global Market
3.2 Top Global Prescription Migraine Medication Companies Ranked by Revenue
3.3 Global Prescription Migraine Medication Revenue by Companies
3.4 Top 3 and Top 5 Prescription Migraine Medication Companies in Global Market, by Revenue in 2022
3.5 Global Companies Prescription Migraine Medication Product Type
3.6 Tier 1, Tier 2 and Tier 3 Prescription Migraine Medication Players in Global Market
3.6.1 List of Global Tier 1 Prescription Migraine Medication Companies
3.6.2 List of Global Tier 2 and Tier 3 Prescription Migraine Medication Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Prescription Migraine Medication Market Size Markets, 2022＆2029
4.1.2 Sumatriptan
4.1.3 Rizatriptan
4.1.4 Others
4.2 By Type – Global Prescription Migraine Medication Revenue＆Forecasts
4.2.1 By Type – Global Prescription Migraine Medication Revenue, 2018-2023
4.2.2 By Type – Global Prescription Migraine Medication Revenue, 2024-2029
4.2.3 By Type – Global Prescription Migraine Medication Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Prescription Migraine Medication Market Size, 2022＆2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Drug Store
5.2 By Application – Global Prescription Migraine Medication Revenue＆Forecasts
5.2.1 By Application – Global Prescription Migraine Medication Revenue, 2018-2023
5.2.2 By Application – Global Prescription Migraine Medication Revenue, 2024-2029
5.2.3 By Application – Global Prescription Migraine Medication Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Prescription Migraine Medication Market Size, 2022＆2029
6.2 By Region – Global Prescription Migraine Medication Revenue＆Forecasts
6.2.1 By Region – Global Prescription Migraine Medication Revenue, 2018-2023
6.2.2 By Region – Global Prescription Migraine Medication Revenue, 2024-2029
6.2.3 By Region – Global Prescription Migraine Medication Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Prescription Migraine Medication Revenue, 2018-2029
6.3.2 US Prescription Migraine Medication Market Size, 2018-2029
6.3.3 Canada Prescription Migraine Medication Market Size, 2018-2029
6.3.4 Mexico Prescription Migraine Medication Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Prescription Migraine Medication Revenue, 2018-2029
6.4.2 Germany Prescription Migraine Medication Market Size, 2018-2029
6.4.3 France Prescription Migraine Medication Market Size, 2018-2029
6.4.4 U.K. Prescription Migraine Medication Market Size, 2018-2029
6.4.5 Italy Prescription Migraine Medication Market Size, 2018-2029
6.4.6 Russia Prescription Migraine Medication Market Size, 2018-2029
6.4.7 Nordic Countries Prescription Migraine Medication Market Size, 2018-2029
6.4.8 Benelux Prescription Migraine Medication Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Prescription Migraine Medication Revenue, 2018-2029
6.5.2 China Prescription Migraine Medication Market Size, 2018-2029
6.5.3 Japan Prescription Migraine Medication Market Size, 2018-2029
6.5.4 South Korea Prescription Migraine Medication Market Size, 2018-2029
6.5.5 Southeast Asia Prescription Migraine Medication Market Size, 2018-2029
6.5.6 India Prescription Migraine Medication Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Prescription Migraine Medication Revenue, 2018-2029
6.6.2 Brazil Prescription Migraine Medication Market Size, 2018-2029
6.6.3 Argentina Prescription Migraine Medication Market Size, 2018-2029
6.7 Middle East＆Africa
6.7.1 By Country – Middle East＆Africa Prescription Migraine Medication Revenue, 2018-2029
6.7.2 Turkey Prescription Migraine Medication Market Size, 2018-2029
6.7.3 Israel Prescription Migraine Medication Market Size, 2018-2029
6.7.4 Saudi Arabia Prescription Migraine Medication Market Size, 2018-2029
6.7.5 UAE Prescription Migraine Medication Market Size, 2018-2029
7 Prescription Migraine Medication Companies Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Prescription Migraine Medication Major Product Offerings
7.1.4 GSK Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.1.5 GSK Key News＆Latest Developments
7.2 Teva
7.2.1 Teva Company Summary
7.2.2 Teva Business Overview
7.2.3 Teva Prescription Migraine Medication Major Product Offerings
7.2.4 Teva Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.2.5 Teva Key News＆Latest Developments
7.3 Pfizer
7.3.1 Pfizer Company Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Prescription Migraine Medication Major Product Offerings
7.3.4 Pfizer Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.3.5 Pfizer Key News＆Latest Developments
7.4 Amgen
7.4.1 Amgen Company Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Prescription Migraine Medication Major Product Offerings
7.4.4 Amgen Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.4.5 Amgen Key News＆Latest Developments
7.5 Viatris
7.5.1 Viatris Company Summary
7.5.2 Viatris Business Overview
7.5.3 Viatris Prescription Migraine Medication Major Product Offerings
7.5.4 Viatris Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.5.5 Viatris Key News＆Latest Developments
7.6 Allergan
7.6.1 Allergan Company Summary
7.6.2 Allergan Business Overview
7.6.3 Allergan Prescription Migraine Medication Major Product Offerings
7.6.4 Allergan Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.6.5 Allergan Key News＆Latest Developments
7.7 Grunenthal
7.7.1 Grunenthal Company Summary
7.7.2 Grunenthal Business Overview
7.7.3 Grunenthal Prescription Migraine Medication Major Product Offerings
7.7.4 Grunenthal Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.7.5 Grunenthal Key News＆Latest Developments
7.8 Eli Lilly
7.8.1 Eli Lilly Company Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Prescription Migraine Medication Major Product Offerings
7.8.4 Eli Lilly Prescription Migraine Medication Revenue in Global Market (2018-2023)
7.8.5 Eli Lilly Key News＆Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Prescription Migraine Medication Market Opportunities＆Trends in Global Market
Table 2. Prescription Migraine Medication Market Drivers in Global Market
Table 3. Prescription Migraine Medication Market Restraints in Global Market
Table 4. Key Players of Prescription Migraine Medication in Global Market
Table 5. Top Prescription Migraine Medication Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Prescription Migraine Medication Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Prescription Migraine Medication Revenue Share by Companies, 2018-2023
Table 8. Global Companies Prescription Migraine Medication Product Type
Table 9. List of Global Tier 1 Prescription Migraine Medication Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Prescription Migraine Medication Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Prescription Migraine Medication Revenue, (US$, Mn), 2022＆2029
Table 12. By Type - Prescription Migraine Medication Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Prescription Migraine Medication Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Prescription Migraine Medication Revenue, (US$, Mn), 2022＆2029
Table 15. By Application - Prescription Migraine Medication Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Prescription Migraine Medication Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Prescription Migraine Medication Revenue, (US$, Mn), 2022＆2029
Table 18. By Region - Global Prescription Migraine Medication Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Prescription Migraine Medication Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Prescription Migraine Medication Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Prescription Migraine Medication Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Prescription Migraine Medication Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Prescription Migraine Medication Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Prescription Migraine Medication Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Prescription Migraine Medication Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Prescription Migraine Medication Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Prescription Migraine Medication Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East＆Africa Prescription Migraine Medication Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East＆Africa Prescription Migraine Medication Revenue, (US$, Mn), 2024-2029
Table 30. GSK Company Summary
Table 31. GSK Prescription Migraine Medication Product Offerings
Table 32. GSK Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 33. GSK Key News＆Latest Developments
Table 34. Teva Company Summary
Table 35. Teva Prescription Migraine Medication Product Offerings
Table 36. Teva Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 37. Teva Key News＆Latest Developments
Table 38. Pfizer Company Summary
Table 39. Pfizer Prescription Migraine Medication Product Offerings
Table 40. Pfizer Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 41. Pfizer Key News＆Latest Developments
Table 42. Amgen Company Summary
Table 43. Amgen Prescription Migraine Medication Product Offerings
Table 44. Amgen Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 45. Amgen Key News＆Latest Developments
Table 46. Viatris Company Summary
Table 47. Viatris Prescription Migraine Medication Product Offerings
Table 48. Viatris Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 49. Viatris Key News＆Latest Developments
Table 50. Allergan Company Summary
Table 51. Allergan Prescription Migraine Medication Product Offerings
Table 52. Allergan Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 53. Allergan Key News＆Latest Developments
Table 54. Grunenthal Company Summary
Table 55. Grunenthal Prescription Migraine Medication Product Offerings
Table 56. Grunenthal Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 57. Grunenthal Key News＆Latest Developments
Table 58. Eli Lilly Company Summary
Table 59. Eli Lilly Prescription Migraine Medication Product Offerings
Table 60. Eli Lilly Prescription Migraine Medication Revenue (US$, Mn)＆(2018-2023)
Table 61. Eli Lilly Key News＆Latest Developments
List of Figures
Figure 1. Prescription Migraine Medication Segment by Type in 2022
Figure 2. Prescription Migraine Medication Segment by Application in 2022
Figure 3. Global Prescription Migraine Medication Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Prescription Migraine Medication Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Prescription Migraine Medication Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Prescription Migraine Medication Revenue in 2022
Figure 8. By Type - Global Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 9. By Application - Global Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 10. By Type - Global Prescription Migraine Medication Revenue, (US$, Mn), 2022＆2029
Figure 11. By Type - Global Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 12. By Application - Global Prescription Migraine Medication Revenue, (US$, Mn), 2022＆2029
Figure 13. By Application - Global Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 14. By Region - Global Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 15. By Country - North America Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 16. US Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 20. Germany Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 21. France Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 28. China Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 32. India Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 34. Brazil Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East＆Africa Prescription Migraine Medication Revenue Market Share, 2018-2029
Figure 37. Turkey Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Prescription Migraine Medication Revenue, (US$, Mn), 2018-2029
Figure 41. GSK Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 42. Teva Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 43. Pfizer Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 44. Amgen Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 45. Viatris Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 46. Allergan Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 47. Grunenthal Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)
Figure 48. Eli Lilly Prescription Migraine Medication Revenue Year Over Year Growth (US$, Mn)＆(2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 片頭痛処方薬のグローバル市場展望 2023年-2029年：スマトリプタン、リザトリプタン、その他
  • 処方頭痛薬のグローバル市場展望 2023年-2029年：スマトリプタン、リザトリプタン、その他
  • 片頭痛治療薬のグローバル市場展望 2023年-2029年：非ステロイド性抗炎症薬、アセトアミノフェン、トリプタン、その他
  • OTC片頭痛薬のグローバル市場展望 2023年-2029年：NSAIDs、アセトアミノフェン、その他
  • 体重管理薬のグローバル市場展望 2023年-2029年：カプセル型、フレーク型
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC14530 )"処方片頭痛薬のグローバル市場展望 2023年-2029年：スマトリプタン、リザトリプタン、その他" (英文：Prescription Migraine Medication Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。